|
|
Article: CytRx Gains HIV Vaccine License Through Second UMSS Contract.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
It seems CytRx Corp. is going back to the well.
The company jumped into the HIV vaccine development fray by licensing a DNA-based product from the University of Massachusetts Medical School, with whom CytRx recently established an RNAi-based relationship. Also, from the outset of the latest arrangement, a $15 million government grant will fuel early clinical work on the HIV vaccine.
While financial terms of the exclusive worldwide licensing agreement were not disclosed, Los Angeles-based CytRx said the $15 million award - from the National Institutes of Health in Bethesda, Md. - is pegged for pushing the vaccine technology into a ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|